Novo Nordisk presented an early-responder sub-analysis of the STEP UP phase 3b trial at the 33rd European Congress on Obesity (ECO 2026) in Istanbul on May 12, 2026. Among adults on 7.2 mg semaglutide who lost at least 15% of body weight by week 24, mean weight loss reached 27.7% at week 72 (Novo Nordisk, May 12, 2026). The full-cohort 7.2 mg mean stayed at 18.7%, consistent with the headline STEP UP readout published in Lancet Diabetes & Endocrinology in late 2025 (PMID 40961952).
Research-context information only. Semaglutide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the Sub-Analysis Showed
The STEP UP parent trial enrolled approximately 1,407 adults with obesity and without type 2 diabetes across 11 countries, randomising them to 7.2 mg semaglutide, 2.4 mg semaglutide, or placebo for 72 weeks (Wharton et al., Lancet Diabetes Endocrinol, 2025). Headline results: 18.7% mean weight loss at 7.2 mg, 15.6% at 2.4 mg, 3.9% on placebo.
The ECO 2026 sub-analysis carved out a responder subgroup: participants who reached at least 15% body-weight loss by week 24. About one quarter of the 7.2 mg arm met that threshold. Their week-72 mean reached 27.7%. The equivalent 2.4 mg early-responder subset reached 24.8% (Clinical Trials Arena, May 13, 2026).
A companion MRI sub-analysis indicated approximately 84% of weight lost in early responders was fat mass, with abdominal visceral fat reduced by around 30% in that subgroup. Lean-mass loss accounted for the remaining ~16%. Novo framed this body-composition split as evidence that pushing the dose did not worsen the muscle-loss pattern documented at 2.4 mg.
The STEP UP T2D companion trial, in adults with obesity and type 2 diabetes, hit 13.2% mean weight loss on 7.2 mg vs −3.9% placebo at 72 weeks — diabetic cohorts have consistently shown weaker GLP-1 response than non-diabetic cohorts going back to STEP 2.
What It Means for Research-Peptide Buyers
The headline 27.7% number reframes three things buyers should think about.
1. Responder identification is a 24-week question, not a starting-dose question. The sub-analysis defined responders by week-24 outcomes, not baseline characteristics. The trial protocol used standard titration (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over roughly 16 weeks, then continued stepping up to 4.8 mg and finally 7.2 mg). Trial subjects who hit 15% loss by week 24 were the ones who saw the biggest cumulative returns by week 72. Community sources describing the same pattern at lower doses suggest the 6-month mark is the practical inflection point for evaluating whether a protocol is working.
2. Vial economics shift hard at 7.2 mg. A 10 mg research-peptide vial reconstituted with 1 mL of bacteriostatic water gives 10 mg of total compound. At a 7.2 mg/week protocol, that vial lasts roughly 9 days — not the four-week supply buyers running 2.4 mg titrations typically get. Higher dose means faster vial burn. Buyers stepping protocols up commonly switch to 15 mg or 25 mg vials at this point. See the semaglutide reconstitution guide for the dilution math.
3. The branded price gap widens at the high dose. Branded 7.2 mg pens list north of $1,300/month before insurance or savings cards. Research-peptide vials of 10 mg routinely list at $40-90 from recommended vendors. At three times the molecule per week, the absolute-dollar gap roughly triples vs the 2.4 mg comparison.
For current pricing and stock checks, the /best/semaglutide page ranks vendors by price-per-mg, third-party COA testing, and shipping reliability. The biggest 10-mg-vial discounts active today are on the deals page.
